Cancer chemoprevention research with selenium in the post-SELECT era: Promises and challenges

Junxuan Lu, Jinhui Zhang, Cheng Jiang, Yibin Deng, Nur Özten, Maarten C. Bosland

Research output: Contribution to journalReview article

26 Citations (Scopus)

Abstract

The negative efficacy outcomes of double-blinded, randomized, placebo-controlled Phase III human clinical trials with selenomethionine (SeMet) and SeMet-rich selenized-yeast (Se-yeast) for prostate cancer prevention and Se-yeast for prevention of nonsmall cell lung cancer (NSCLC) in North America lead to rejection of SeMet/Se-yeast for cancer prevention in Se-adequate populations. We identify 2 major lessons from the outcomes of these trials: 1) the antioxidant hypothesis was tested in wrong subjects or patient populations, and 2) the selection of Se agents was not supported by cell culture and preclinical animal efficacy data as is common in drug development. We propose that next-generation forms of Se (next-gen Se), such as methylselenol precursors, offer biologically appropriate approaches for cancer chemoprevention but these are faced with formidable challenges. Solid mechanism-based preclinical efficacy assessments and comprehensive safety studies with next-gen Se will be essential to revitalize the idea of cancer chemoprevention with Se in the post-SELECT era. We advocate smaller mechanism-driven Phase I/II trials with these next-gen Se to guide and justify future decisions for definitive Phase III chemoprevention efficacy trials.

Original languageEnglish (US)
Pages (from-to)1-17
Number of pages17
JournalNutrition and cancer
Volume68
Issue number1
DOIs
StatePublished - Jan 2 2016

Fingerprint

Selenomethionine
Chemoprevention
Selenium
Yeasts
Research
Neoplasms
Phase III Clinical Trials
Controlled Clinical Trials
North America
Non-Small Cell Lung Carcinoma
Population
Prostatic Neoplasms
Cell Culture Techniques
Antioxidants
Placebos
Safety
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Medicine (miscellaneous)
  • Oncology
  • Nutrition and Dietetics
  • Cancer Research

Cite this

Lu, Junxuan ; Zhang, Jinhui ; Jiang, Cheng ; Deng, Yibin ; Özten, Nur ; Bosland, Maarten C. / Cancer chemoprevention research with selenium in the post-SELECT era : Promises and challenges. In: Nutrition and cancer. 2016 ; Vol. 68, No. 1. pp. 1-17.
@article{78679355805347b3a5ae4cbe64dddfbe,
title = "Cancer chemoprevention research with selenium in the post-SELECT era: Promises and challenges",
abstract = "The negative efficacy outcomes of double-blinded, randomized, placebo-controlled Phase III human clinical trials with selenomethionine (SeMet) and SeMet-rich selenized-yeast (Se-yeast) for prostate cancer prevention and Se-yeast for prevention of nonsmall cell lung cancer (NSCLC) in North America lead to rejection of SeMet/Se-yeast for cancer prevention in Se-adequate populations. We identify 2 major lessons from the outcomes of these trials: 1) the antioxidant hypothesis was tested in wrong subjects or patient populations, and 2) the selection of Se agents was not supported by cell culture and preclinical animal efficacy data as is common in drug development. We propose that next-generation forms of Se (next-gen Se), such as methylselenol precursors, offer biologically appropriate approaches for cancer chemoprevention but these are faced with formidable challenges. Solid mechanism-based preclinical efficacy assessments and comprehensive safety studies with next-gen Se will be essential to revitalize the idea of cancer chemoprevention with Se in the post-SELECT era. We advocate smaller mechanism-driven Phase I/II trials with these next-gen Se to guide and justify future decisions for definitive Phase III chemoprevention efficacy trials.",
author = "Junxuan Lu and Jinhui Zhang and Cheng Jiang and Yibin Deng and Nur {\"O}zten and Bosland, {Maarten C.}",
year = "2016",
month = "1",
day = "2",
doi = "10.1080/01635581.2016.1105267",
language = "English (US)",
volume = "68",
pages = "1--17",
journal = "Nutrition and Cancer",
issn = "0163-5581",
publisher = "Routledge",
number = "1",

}

Cancer chemoprevention research with selenium in the post-SELECT era : Promises and challenges. / Lu, Junxuan; Zhang, Jinhui; Jiang, Cheng; Deng, Yibin; Özten, Nur; Bosland, Maarten C.

In: Nutrition and cancer, Vol. 68, No. 1, 02.01.2016, p. 1-17.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Cancer chemoprevention research with selenium in the post-SELECT era

T2 - Promises and challenges

AU - Lu, Junxuan

AU - Zhang, Jinhui

AU - Jiang, Cheng

AU - Deng, Yibin

AU - Özten, Nur

AU - Bosland, Maarten C.

PY - 2016/1/2

Y1 - 2016/1/2

N2 - The negative efficacy outcomes of double-blinded, randomized, placebo-controlled Phase III human clinical trials with selenomethionine (SeMet) and SeMet-rich selenized-yeast (Se-yeast) for prostate cancer prevention and Se-yeast for prevention of nonsmall cell lung cancer (NSCLC) in North America lead to rejection of SeMet/Se-yeast for cancer prevention in Se-adequate populations. We identify 2 major lessons from the outcomes of these trials: 1) the antioxidant hypothesis was tested in wrong subjects or patient populations, and 2) the selection of Se agents was not supported by cell culture and preclinical animal efficacy data as is common in drug development. We propose that next-generation forms of Se (next-gen Se), such as methylselenol precursors, offer biologically appropriate approaches for cancer chemoprevention but these are faced with formidable challenges. Solid mechanism-based preclinical efficacy assessments and comprehensive safety studies with next-gen Se will be essential to revitalize the idea of cancer chemoprevention with Se in the post-SELECT era. We advocate smaller mechanism-driven Phase I/II trials with these next-gen Se to guide and justify future decisions for definitive Phase III chemoprevention efficacy trials.

AB - The negative efficacy outcomes of double-blinded, randomized, placebo-controlled Phase III human clinical trials with selenomethionine (SeMet) and SeMet-rich selenized-yeast (Se-yeast) for prostate cancer prevention and Se-yeast for prevention of nonsmall cell lung cancer (NSCLC) in North America lead to rejection of SeMet/Se-yeast for cancer prevention in Se-adequate populations. We identify 2 major lessons from the outcomes of these trials: 1) the antioxidant hypothesis was tested in wrong subjects or patient populations, and 2) the selection of Se agents was not supported by cell culture and preclinical animal efficacy data as is common in drug development. We propose that next-generation forms of Se (next-gen Se), such as methylselenol precursors, offer biologically appropriate approaches for cancer chemoprevention but these are faced with formidable challenges. Solid mechanism-based preclinical efficacy assessments and comprehensive safety studies with next-gen Se will be essential to revitalize the idea of cancer chemoprevention with Se in the post-SELECT era. We advocate smaller mechanism-driven Phase I/II trials with these next-gen Se to guide and justify future decisions for definitive Phase III chemoprevention efficacy trials.

UR - http://www.scopus.com/inward/record.url?scp=84957977658&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957977658&partnerID=8YFLogxK

U2 - 10.1080/01635581.2016.1105267

DO - 10.1080/01635581.2016.1105267

M3 - Review article

C2 - 26595411

AN - SCOPUS:84957977658

VL - 68

SP - 1

EP - 17

JO - Nutrition and Cancer

JF - Nutrition and Cancer

SN - 0163-5581

IS - 1

ER -